OBMPライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products...

Stats
本日の出来高	58 992.00
平均出来高	8 379.00
時価総額	0.00
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2020-09-24	Chilcott, Iii Thomas E.	Buy	0
2020-06-05	Ruxin Michael I	Buy	0
2020-05-07	Head Jonathan Frederick	Buy	166 667	Shares of Common Stock
2019-04-24	Holcomb Robert Neal	Buy	3 000 000	Employee Stock Option (right to buy)
2019-04-24	Hoverman Daniel S.	Buy	3 000 000	Employee Stock Option (right to buy)

INSIDER POWER
0.00
Last 25 transactions
Buy: 69 901 401 \| Sell: 14 397 245

Theralink Technologies, 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Theralink Technologies, 財務諸表

Annual	2021
収益:	$505 604
総利益:	$388 148 (76.77 %)
EPS:	$-0.00124

FY	2021
収益:	$505 604
総利益:	$388 148 (76.77 %)
EPS:	$-0.00124

FY	2020
収益:	$181 229
総利益:	$128 642 (70.98 %)
EPS:	$-0.0374

FY	2019
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-19.00

Financial Reports:

No articles found.

Theralink Technologies,

Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. The company through its patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. The company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. The company is headquartered in Golden, Colorado.